• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Eisai takes baton from Biogen as next Alzheimer's prospect follows in Aduhelm's footprints | FierceB


<